The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

3800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-07-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish the large COPD cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices and to monitor and improve clinical outcomes in this disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China

NCT04853238

Pulmonary Disease, Chronic Obstructive

COMPLETED

Early COPD for China Pulmonary Health Study Stage II

NCT05028985

Obstructive Pulmonary Disease

RECRUITING

Air Pollution and Health of COPD Patients

NCT05076630

Chronic Obstructive Pulmonary Disease

COMPLETED

Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China

NCT04853225

Pulmonary Disease, Chronic Obstructive

COMPLETED

Predictive Value of Inflammatory Biomarkers and FEV1 for COPD

NCT03532893

COPD FEV1

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 5-year multi-center observational prospective longitudinal cohort study to to establish the large COPD cohort and biological database in China, including COPD subjects( n= 3000) and GOLD 0 subjects (n= 800).Sites Investigators will be respiratory physicians working in the respiratory department of our sites, which must be tier 2 or tier 3 hospitals in China, with the equipment and ability to conduct pulmonary function test, HRCT.Patients must meet all the inclusion criteria and none of the exclusion criteria.No additional investigational drugs will be applied to the patients. Full analysis set will be used for all analyses. Missing data will be analysed as it is. Statistical analysis will be conducted by epidemiology \& statistics work group from Chinese Academy of Sciences, using SAS and SUDAAN software. An electronic data capture system will be used in this study. Paper-based questionnaire administration will also be used.Questionnaire variables will be checked before data entry.During the study, PI will be in charge of the monitoring of the whole procedure. Two working group will do the data cleaning and data analysing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD group

The post-bronchodilator FEV1/FVC ratio \< 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease

COPD group

Intervention Type OTHER

The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.

GOLD 0 group

GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COPD group

The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 40-75 years
* COPD group: baseline post-bronchodilator FEV1/FVC \< 0.7
* GOLD 0 group: individuals with chronic respiratory symptoms and/or high risk factors
* Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years

Exclusion Criteria

* Acute exacerbation in the past 3 months
* Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc
* The usual criteria of serious uncontrolled diseases
* thoracic or abdominal surgery in the last 3 months
* eye surgery in the last three months
* retinal detachment
* myocardial infarction in the last 3 months
* admission to hospital for any cardiac condition in the last month
* heart rate over 120 beats per minute
* antibacterial chemotherapy for tuberculosis
* pregnant or breast feeding

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No